Alexander J. Bridges

8.4k citations

62 papers · 7.1k indexed · 3 hit papers · h-index 27

Oncology top 1%
- HER2/EGFR in Cancer Research 16
Organic Chemistry top 1%
- Quinazolinone synthesis and applications 11
- Synthesis and Characterization of Heterocyclic Compounds 9
- Synthesis and biological activity 6
- Synthesis and Biological Evaluation 5
- Coordination Chemistry and Organometallics 5
Molecular Biology top 1%
- PI3K/AKT/mTOR signaling in cancer 8
- Melanoma and MAPK Pathways 5
Cancer Research top 5%
Immunology and Allergy top 2%

Co-authors: Alan R. Saltiel David T. Dudley Stuart J. Decker Long Pang David W. Fry Wilbur R. Leopold Amy McMichael James M. Nelson
Cited by: Oncology Organic Chemistry Molecular Biology
Partner nations: United States New Zealand Japan

In The Last Decade

Alexander J. Bridges

61 papers receiving 6.9k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1999 Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade.
1994 A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

Peers

Countries citing papers authored by Alexander J. Bridges

Since Specialization

Citations

This map shows the geographic impact of Alexander J. Bridges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander J. Bridges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander J. Bridges more than expected).

Fields of papers citing papers by Alexander J. Bridges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander J. Bridges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander J. Bridges. The network helps show where Alexander J. Bridges may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Alexander J. Bridges, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alexander J. Bridges Line = papers co-authored together Alexander J. Bridges links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics Carrie S. Tambo,Sarvind Tripathi,B. Gayani K. Perera,Dustin J. Maly,Alexander J. Bridges,Gert Kiss,Seth M. Rubin	2023	8
2	Disruptin, a cell-penetrating peptide degrader of EGFR Ranjit K. Mehta,Sushmita Shukla,Susmita G. Ramanand,Vishal Somnay,Alexander J. Bridges,Theodore S. Lawrence,Mukesh K. Nyati	2021	5
3	The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Stephen D. Barrett,Alexander J. Bridges,David T. Dudley,Alan R. Saltiel,James H. Fergus,Cathlin Flamme,Amy M. Delaney,Michael D. Kaufman,S Lepage,Wilbur R. Leopold,Sally Przybranowski,Judith S. Sebolt–Leopold,Keri Van Becelaere,Annette M. Doherty,Robert M. Kennedy,Dan Marston,W. Allen Howard,Yvonne Smith,Joseph S. Warmus,Haile Tecle	2008	222
4	2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase) Joseph S. Warmus,Cathlin Flamme,Lu Yan Zhang,Stephen D. Barrett,Alexander J. Bridges,Huifen Chen,Richard Gowan,Michael D. Kaufman,Judy Sebolt-Leopold,Wilbur R. Leopold,Ronald L. Merriman,Jeffrey F. Ohren,A.G. Pavlovsky,Sally Przybranowski,Haile Tecle,Heather Valik,Christopher E. Whitehead,Erli Zhang	2008	60
5	Synthesis and structure–activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases Jeff B. Smaill,Edward N. Baker,R J Booth,Alexander J. Bridges,James M. Dickson,Ellen M. Dobrusin,Ivan Ivanović,Alan J. Kraker,Ho H. Lee,Elizabeth A. Lunney,Daniel F. Ortwine,Brian D. Palmer,John Quin,C.J. Squire,Andrew M. Thompson,William A. Denny	2007	28
6	Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. Michael D. Kaufman,Stephen D. Barrett,Cathlin Flamme,Joseph S. Warmus,Yvonne Smith,Manoj Cheriyan,Luyan Zhang,Haile Tecle,Judith S. Sebolt–Leopold,Heather Valik,Richard Gowan,Keri Van Becelaere,Ronald L. Merriman,Sally Przybranowski,Jeffrey F. Ohren,Christopher E. Whitehead,Wilbur R. Leopold,Ellen M. Dobrusin,Alexander J. Bridges	2004	1
7	Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. Jeff B. Smaill,Gordon W. Rewcastle,Alexander J. Bridges,Hairong Zhou,H. D. Hollis Showalter,David W. Fry,James M. Nelson,Veronika Sherwood,William L. Elliott,Patrick W. Vincent,Dana E. DeJohn,Joseph A. Loo,Kenneth D. Greis,O. Helen Chan,Eric L. Reyner,Elke Lipka,William A. Denny	2000	12
8	Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivobreakdown → Judith S. Sebolt–Leopold,David T. Dudley,Román Herrera,Keri Van Becelaere,Amy M. Wiland,Richard Gowan,Haile Tecle,Stephen D. Barrett,Alexander J. Bridges,Sally Przybranowski,Wilbur R. Leopold,Alan R. Saltiel	1999	804
9	Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor David W. Fry,Alexander J. Bridges,William A. Denny,Annette M. Doherty,Kenneth D. Greis,James L. Hicks,Kenneth E. Hook,Paul R. Keller,Wilbur R. Leopold,Joseph A. Loo,Dennis J. McNamara,James M. Nelson,Veronika Sherwood,Jeff B. Smaill,Susanne Trumpp-Kallmeyer,Ellen M. Dobrusin	1998	344
10	STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO William A. Denny,Gordon W. Rewcastle,Alexander J. Bridges,David W. Fry,Alan J. Kraker	1996	23
11	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. Gordon W. Rewcastle,William A. Denny,Alexander J. Bridges,Hairong Zhou,Donna R. Cody,Amy McMichael,David W. Fry	1995	223
12	A synthetic inhibitor of the mitogen-activated protein kinase cascade.breakdown → David T. Dudley,Long Pang,Stuart J. Decker,Alexander J. Bridges,Alan R. Saltiel	1995	2522
13	Inhibitors of protein tyrosine kinases David W. Fry,Alexander J. Bridges	1995	21
14	The synthesis of three 4-substitutedbenzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase Alexander J. Bridges,Arthur Lee,C. Schwartz,Murray J. Towle,Bruce A. Littlefield	1993	22
15	New 8-(trifluoromethyl)-substituted quinolones. The benefits of the 8-fluoro group with reduced phototoxic risk Joseph P. Sanchez,Alexander J. Bridges,R. A. BUCSH,J. M. DOMAGALA,Rocco D. Gogliotti,Susan E. Hagen,Carl L. Heifetz,E. Themis Joannides,J. C. Sesnie	1992	20
16	N6-Bicycloalkyladenosines with unusually high potency and selectivity for the adenosine A1 receptor Bharat K. Trivedi,Alexander J. Bridges,William C. Patt,Steven R. Priebe,Robert F. Bruns	1989	42
17	N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor Alexander J. Bridges,Robert F. Bruns,Daniel F. Ortwine,Steven R. Priebe,Deedee L. Szotek,Bharat K. Trivedi	1988	64
18	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity Alexander J. Bridges,Walter H. Moos,Deedee L. Szotek,Bharat K. Trivedi,James A. Bristol,Thomas G. Heffner,Robert F. Bruns,David A. Downs	1987	39
19	An investigation of the chemistry of phenylsulphonylcyclopentadiene Alexander J. Bridges,John W. Fischer	1983	6
20	Phenylthiocopper trimethylphosphite complex. A reagent for the preparation of thioallenes. Alexander J. Bridges	1980	9

About Alexander J. Bridges

Alexander J. Bridges is a scholar working on Organic Chemistry, Physiology and Oncology, having authored 62 papers that have together received 7.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (16 papers), Quinazolinone synthesis and applications (11 papers), Synthesis and Characterization of Heterocyclic Compounds (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Synthesis and biological activity (6 papers), Melanoma and MAPK Pathways (5 papers), Synthesis and Biological Evaluation (5 papers) and Coordination Chemistry and Organometallics (5 papers). The work is most often cited by research in Oncology (2.1k citations), Organic Chemistry (2.0k citations) and Molecular Biology (4.2k citations). Alexander J. Bridges has collaborated with scholars based in United States, New Zealand and Japan. Frequent co-authors include Alan R. Saltiel, David T. Dudley, Stuart J. Decker, Long Pang, David W. Fry, Wilbur R. Leopold, Amy McMichael, James M. Nelson, Alan J. Kraker and Gordon W. Rewcastle.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact